Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitamin B and disability

This article was originally published in The Tan Sheet

Executive Summary

Low serum concentrations of selenium and vitamins B6 and B12 predict an increased rate of disability in activities of daily living (ADLs), according to a Nov. 27 Archives of Internal Medicine study. ADLs include bathing, dressing and eating, according to the authors. Benedetta Bartarli, Division of Nutritional Sciences, Cornell University, Ithaca, NY et al., conclude while the results suggest poor nutritional status contributes to the disablement process, "these results do not imply a beneficial effect of nutrient supplementation on the prevention of disability but rather suggest that nutritional status is one of the key factors to be considered." Women in the lowest quartile of serum concentrations of vitamin B6 (hazard ratio 1.31), vitamin B12 (HR 1.40) and selenium (HR 1.38) had "significantly higher risk of disability in ADLs" compared with women in the upper 3 quartiles, the researchers say. The longitudinal study included 643 women aged 65 or older enrolled in the Women's Health & Aging Study I. The women were assessed prospectively at six-month intervals from 1992 to 1995...

You may also be interested in...



European Debut For CMR Surgical’s Versius Surgical Robot In Two UK NHS Hospitals

CMR Surgical’s Versius robotic system is now live in the UK NHS, the company announced 20 February.

Teva Emerges From Restructuring Ready To Grow

Despite seeing an 8% drop in global turnover in 2019, an upbeat Teva says the completion of its restructuring plan has positioned the company to increase its turnover through newly-launched products – including biosimilars, brands and new generics – as well as improve its profit margins through manufacturing optimization.

Executives On The Move: Eisai Taps Celgene And Sanofi VPs For Its Team, And Freeline Selects A CEO

Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.

Topics

UsernamePublicRestriction

Register

PS100014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel